Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer

Next Previous
X
Search
Trial Profile

A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms PemBla

    • Most Recent Events

    • 22 Jul 2020 This trial is completed (Global End Date: 26 Jun 2019), according to European Clinical Trials Database record.
    • 15 Jul 2020 Status changed from recruiting to discontinued.
    • 16 Feb 2019 Results (n=4) of intravesical pembrolizumab evaluating safety and tolerability in recurrent non-muscle invasive bladder cancer were presented at the 2019 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top